Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Trish Hammerschmidt"'
Autor:
Foluso O. Ademuyiwa, Donald W. Northfelt, Tracey O’Connor, Ellis Levine, Jingqin Luo, Yu Tao, Jeremy Hoog, Marie L. Laury, Tracy Summa, Trish Hammerschmidt, Zhanfang Guo, Ashley Frith, Katherine Weilbaecher, Mateusz Opyrchal, Rebecca Aft, Katherine Clifton, Rama Suresh, Nusayba Bagegni, Ian S. Hagemann, Michael D. Iglesia, Cynthia X. Ma
Publikováno v:
npj Breast Cancer, Vol 9, Iss 1, Pp 1-9 (2023)
Abstract Patients with ER+/HER2+ breast cancer (BC) are less likely to achieve pathological complete response (pCR) after chemotherapy with dual HER2 blockade than ER−/HER2+ BC. Endocrine therapy plus trastuzumab is effective in advanced ER+/HER2+
Externí odkaz:
https://doaj.org/article/49d5c74d8dba4b95b0b0ea0d7e2de4d4
Autor:
Andrew A. Davis, Leonel Hernandez-Aya, Jingqin Luo, Mateusz Opyrchal, Foluso O. Ademuyiwa, Nusayba A. Bagegni, Katherine K. Clifton, Jill Anderson, Trish Hammerschmidt, Leslie Nehring, David DeNardo, Mark Watson, Rebecca Aft, Cynthia Ma, Katherine Weilbaecher
Publikováno v:
Cancer Research. 83:P3-06
Background: Neoadjuvant immune checkpoint inhibition (ICI) in combination with chemotherapy is approved for patients with high-risk, early-stage triple-negative breast cancer (TNBC) based on improved outcomes in the KEYNOTE-522 trial. However, some p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::62ee39f9967d655e9eda0cfed9531ebd
https://doi.org/10.1158/1538-7445.sabcs22-p3-06-07
https://doi.org/10.1158/1538-7445.sabcs22-p3-06-07
Autor:
Foluso O Ademuyiwa, Donald Northfelt, Tracey O'Connor, Ellis Levine, Jingqin Luo, Yu Tao, Jeremy Hoog, Marie Laury, Tracy Summa, Trish Hammerschmidt, Zhanfang Guo, Ashley Frith, Katherine Weilbaecher, Mateusz Opyrchal, Rebecca Aft, Katherine Clifton, Rama Suresh, Nusayba Bagegni, Ian S Hagemann, Cynthia X Ma
Publikováno v:
Cancer Research. 82:P2-13
Background Patients (pts) with ER+ HER2+ breast cancer (BC) are less likely to achieve pathological complete response (pCR) after neoadjuvant chemotherapy with dual HER2 blockade than pts with ER- HER2+ BC. Endocrine therapy (ET) plus trastuzumab is
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::fff7f1b3b9761c929a5417b5396a308b
https://doi.org/10.1158/1538-7445.sabcs21-p2-13-01
https://doi.org/10.1158/1538-7445.sabcs21-p2-13-01